City Therapeutics
City Therapeutics develops RNA-interference therapeutics and an engineering platform across disease areas.
$99.5MSeries B
Role not disclosedI
Invus
Activity from announced rounds
Activity in this selectionOct 24, 2026 · Enterprise software · Jan 1, 2026
Invus is the investment-firm name used by Encoded Therapeutics and in LifeMine transaction-counsel coverage.
Recorded funding activity
Encoded develops precision gene therapies for neurological disorders. LifeMine uses fungal genomes for drug discovery, while City develops RNA-interference medicines. The records identify different therapeutic approaches without substituting an unnamed parent or fund.
- Rounds participated in
- 2
- Confirmed lead rounds
- — 2 roles undisclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $192M 2 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
2 in this selectionContraline
Develops hormonal and non-hormonal male contraceptives for men and couples globally
$92.5MSeries B
Role not disclosed